<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102125</url>
  </required_header>
  <id_info>
    <org_study_id>160808</org_study_id>
    <nct_id>NCT03102125</nct_id>
  </id_info>
  <brief_title>Stress Cardiac MRI in Heart Transplant</brief_title>
  <official_title>Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount
      of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft
      dysfunction in contrast to those with normal graft function. The investigators hypothesize
      that patients with nonspecific allograft dysfunction will demonstrate decreased myocardial
      perfusion reserve, related to microvascular allograft vasculopathy, compared to those with
      normal graft function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult heart-transplant patients, excluding those with a GFR less than 30 mL/min/1.73m2,
      contraindications to MRI and allergies to either regadenoson or gadolinium contrast, will be
      enrolled over 10 months. Patients will be recruited from UCSD. The investigators will
      specifically enroll patients with nonspecific allograft dysfunction and patients with normal
      graft function.

      Brief protocol:

      Cardiac MRI is performed. Cine images in standard views are obtained. T2 mapping sequences
      are performed on short axis images. For stress imaging, intravenous regadenoson is given as a
      0.4 mg bolus followed by a 5 mL saline flush. After 30 seconds, short-axis images are
      acquired for 30 consecutive heartbeats with administration of gadolinium. Rest imaging is
      performed 30 minutes after stress imaging. Lastly, late gadolinium enhancement images are
      obtained in standard views. Images are analyzed offline by a blinded independent reader.
      Patients will be followed for one month after enrollment for MACE.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Perfusion Reserve</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial ischemia/infarction</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for cardiac related causes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-transplantation</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular causes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late gadolinium enhancement</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean segmental T1 values of the left ventricle</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Heart Transplant Failure and Rejection</condition>
  <arm_group>
    <arm_group_label>Nonspecific allograft dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal graft function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>For use in stress myocardial perfusion imaging.</description>
    <arm_group_label>Nonspecific allograft dysfunction</arm_group_label>
    <arm_group_label>Normal graft function</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years old.

          -  At least three months status post heart transplantation.

          -  Heart-transplant patients with normal graft function (left ventricular ejection
             fraction equal to or greater than 55%) and no prior history of clinically significant
             acute rejection episodes that required modification of the immunosuppressive regimen
             or cardiac allograft vasculopathy.

          -  Heart-transplant patients with nonspecific allograft dysfunction (left ventricular
             ejection fraction equal to or less than 50% AND decrease from post-transplant baseline
             ejection fraction by an absolute difference of 10% or greater, no formal diagnosis of
             allograft vasculopathy by coronary angiogram or coronary vascular ultrasonography, and
             no history of prior acute rejection episodes known to have decreased left ventricular
             ejection fraction to or less than 50%).

        Exclusion Criteria:

          -  Biopsy proven acute rejection episode in the past 3 months.

          -  Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary
             syndrome in the past 3 months.

          -  Uncontrolled obstructive ventilatory disease including asthma and COPD.

          -  Second or third degree AV nodal block.

          -  Sinus node dysfunction.

          -  Contraindications to MRI including pacemakers or implantable
             cardioverter-defibrillators.

          -  Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2.

          -  Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse
             reaction to adenosine will be assessed on a case-by-case basis.

          -  Any invasive procedure, including endomyocardial biopsy and left coronary angiogram,
             performed within one week.

          -  Systolic blood pressure greater than 180 or less than 85 mmHg.

          -  Diastolic blood pressure greater than 120 or less than 40 mmHg.

          -  Resting heart rate greater than 120 or less than 45 beats per minute.

          -  Severe claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Kim, MD</last_name>
    <phone>8582460638</phone>
    <email>pjk017@ucsd.edu</email>
  </overall_contact>
  <results_reference>
    <citation>Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, Kirk R, Rahmel AO, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. J Heart Lung Transplant. 2011 Oct;30(10):1078-94. doi: 10.1016/j.healun.2011.08.003.</citation>
    <PMID>21962016</PMID>
  </results_reference>
  <results_reference>
    <citation>Berry GJ, Angelini A, Burke MM, Bruneval P, Fishbein MC, Hammond E, Miller D, Neil D, Revelo MP, Rodriguez ER, Stewart S, Tan CD, Winters GL, Kobashigawa J, Mehra MR. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011 Jun;30(6):601-11. doi: 10.1016/j.healun.2011.02.015.</citation>
    <PMID>21555100</PMID>
  </results_reference>
  <results_reference>
    <citation>Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010 Aug;29(8):914-56. doi: 10.1016/j.healun.2010.05.034.</citation>
    <PMID>20643330</PMID>
  </results_reference>
  <results_reference>
    <citation>Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987 Oct;76(4):827-34.</citation>
    <PMID>3308166</PMID>
  </results_reference>
  <results_reference>
    <citation>Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, Suh J, Frei B, Mudge GH, Selwyn AP, Ganz P. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002 Mar 30;359(9312):1108-13.</citation>
    <PMID>11943259</PMID>
  </results_reference>
  <results_reference>
    <citation>Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Elashoff B, Baron H, Yee J, Valantine HA; IMAGE Study Group. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010 May 20;362(20):1890-900. doi: 10.1056/NEJMoa0912965. Epub 2010 Apr 22.</citation>
    <PMID>20413602</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhalodolia R, Cortese C, Graham M, Hauptman PJ. Fulminant acute cellular rejection with negative findings on endomyocardial biopsy. J Heart Lung Transplant. 2006 Aug;25(8):989-92. Epub 2006 Jun 30.</citation>
    <PMID>16890123</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller CA, Sarma J, Naish JH, Yonan N, Williams SG, Shaw SM, Clark D, Pearce K, Stout M, Potluri R, Borg A, Coutts G, Chowdhary S, McCann GP, Parker GJ, Ray SG, Schmitt M. Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy. J Am Coll Cardiol. 2014 Mar 4;63(8):799-808. doi: 10.1016/j.jacc.2013.07.119. Epub 2013 Dec 18.</citation>
    <PMID>24355800</PMID>
  </results_reference>
  <results_reference>
    <citation>Marie PY, Angioï M, Carteaux JP, Escanye JM, Mattei S, Tzvetanov K, Claudon O, Hassan N, Danchin N, Karcher G, Bertrand A, Walker PM, Villemot JP. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. J Am Coll Cardiol. 2001 Mar 1;37(3):825-31.</citation>
    <PMID>11693758</PMID>
  </results_reference>
  <results_reference>
    <citation>Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson. 2009 Mar 12;11:7. doi: 10.1186/1532-429X-11-7. Review.</citation>
    <PMID>19284612</PMID>
  </results_reference>
  <results_reference>
    <citation>Kübrich M, Petrakopoulou P, Kofler S, Nickel T, Kaczmarek I, Meiser BM, Reichart B, von Scheidt W, Weis M. Impact of coronary endothelial dysfunction on adverse long-term outcome after heart transplantation. Transplantation. 2008 Jun 15;85(11):1580-7. doi: 10.1097/TP.0b013e318170b4cd.</citation>
    <PMID>18551063</PMID>
  </results_reference>
  <results_reference>
    <citation>Solberg OG, Ragnarsson A, Kvarsnes A, Endresen K, Kongsgård E, Aakhus S, Gullestad L, Stavem K, Aaberge L. Reference interval for the index of coronary microvascular resistance. EuroIntervention. 2014 Jan 22;9(9):1069-75. doi: 10.4244/EIJV9I9A181.</citation>
    <PMID>24457279</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>May 5, 2018</last_update_submitted>
  <last_update_submitted_qc>May 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Paul Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>heart transplant, acute graft rejection, chronic graft rejection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

